Ever Supreme Bio Technology , Ltd Receivables

As of the most recent data (June 2026), 6712.TWO shows a receivables of $120M. That compares with $120M in the prior-year period — up 0.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 6712.TWO's receivables is now $120M (was $120M) — a 0.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Ever Supreme Bio Technology , Ltd is outperforming or lagging.

Tracking 6712.TWO's receivables over time shows whether Ever Supreme Bio Technology , Ltd is scaling, shrinking, or reshaping that part of the business. The current reading is $120M That compares with $120M in the prior-year period — up 0.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Ever Supreme Bio Technology , Ltd's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $120M) with ownership activity and broader fundamentals.

Ever Supreme Bio Technology , Ltd's receivables is $120M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.